331 related articles for article (PubMed ID: 24336016)
1. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Verdoia M; Schaffer A; Barbieri L; Cassetti E; Piccolo R; Galasso G; Marino P; Sinigaglia F; De Luca G
J Cardiovasc Pharmacol; 2014 Apr; 63(4):339-50. PubMed ID: 24336016
[TBL] [Abstract][Full Text] [Related]
2. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
[TBL] [Abstract][Full Text] [Related]
4. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
5. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
[TBL] [Abstract][Full Text] [Related]
6. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
9. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Bavishi C; Panwar S; Messerli FH; Bangalore S
Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655
[TBL] [Abstract][Full Text] [Related]
11. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
12. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
13. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.
Verdoia M; Savonitto S; Dudek D; Kedhi E; De Luca G
Vascul Pharmacol; 2021 Apr; 137():106828. PubMed ID: 33385541
[TBL] [Abstract][Full Text] [Related]
18. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
19. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
20. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Jia M; Li Z; Chu H; Li L; Chen K
Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
